Grant R. Zimmermann

Managing Director of Business Development, Blavatnik Biomedical Accelerator

Displaying: 1 - 10 of 49 Results

Control of host homeostatic immunity by a microbiome-derived immunomodulatory lipid

Akkermansia muciniphila, a species of the human gut microbiome, has been robustly associated with positive systemic effects on host metabolism and obesity, favorable response to checkpoint blockade in cancer immunotherapy, and maintenance of…

Investigators

  • Jon Clardy

RGMb-deficient T cells for overcoming resistance to immune checkpoint blockade

Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab at Harvard Medical School has identified that…

Investigators

  • Arlene H. Sharpe
  • Dennis Kasper

PD-L2 modulated dendritic cells for cancer immunotherapy

Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab has identified that dendritic cells (DCs) with…

Investigators

  • Arlene H. Sharpe
  • Dennis Kasper

Rapid point-of-care COVID-19 detection assay by RT-LAMP

The current SARS-CoV-2 pandemic has created an urgent need for rapid point-of-care diagnostic tools. Many of these tests are being developed and are achieving FDA approval. In the face of a sweeping pandemic, assays should require no specialized…

Investigators

  • Constance L. Cepko

Extracellular vesicles for COVID-19 vaccine development

The laboratory of Quan Lu at the Harvard T.H. Chan School of Public Health has developed an innovative vaccine platform that features a novel antigen display technology that has been shown to elicit broadly neutralizing antibody responses from…

Investigators

  • Quan Lu

Self-adjuvanting mRNA platform technology

Researchers in the lab of Prof. George Church at Harvard Medical School have developed a vaccine platform technology that can be applied to fields such as infectious diseases and oncology therapeutics. The team is looking to further demonstrate…

Investigators

  • George M. Church

Compounds that block human cytomegalovirus by targeting the nuclear egress complex

Researchers in Dr. Donald Coen’s lab have identified molecules that inhibit human cytomegalovirus (HCMV) virion egress from the cell, effectively inhibiting HCMV replication. The team is looking to expand on these findings in collaborations that…

Investigators

  • Donald M. Coen

Cancer Treatment through TRPA1 antagonism

Researchers in Joan Brugge’s lab have identified a new cancer therapeutic target in the ion channel transient receptor potential ankyrin 1 (TRPA1). The lab is seeking collaborations with industry partners to expand on these exciting findings. The…

Investigators

  • Joan Brugge

Membrane protein nanoparticles for antigen presentation

Researchers in the lab of Dr. James Chou have engineered a new way to display membrane proteins to enhance vaccine immunogenicity using functionalized nanoparticles. The lab has successfully displayed several viral peptides using this technique and…

Investigators

  • James J. Chou

Platform for AAV Delivery to Skin

Emerging startup: A platform technology from George Church's lab enables delivery of gene therapy via the skin. (Image credit: Carl Schoellhammer, Denitsa Milanova, Humberto Trevino, Cody Cleveland, Jeff Wyckoff, Anna Mandinova, George Church,…

Investigators

  • George M. Church

Page 1 of 5